Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
It is important to note that full oxidation or reduction of Grx1roGFP2 is not equivalent to full oxidation or reduction of the glutathione pool
Clinical research has indicated that FOXO4-DRI has shown promise in the following areas: Targets senescent cells FOXO4-DRI is a synthetic peptide designed to target senescent cells, which are damaged cells that stop dividing but resist apoptosis (programmed cell death)
Food and Drug Administration (FDA) approval Egrifta, cleared in 2010 for one specific indication, reduction of excess visceral fat in HIV-associated lipodystrophy
Alteration in gut microbiota accompanied by increased intestinal permeability and Tfh/Tfr imbalance in patients with active SLE
Eur Heart J 36(11):686697
Collectively, these metabolic shifts delineate actionable targets for metabolic engineering to reinforce intracellular metal chelation and vacuolar sequestration, which represent central mechanisms in Pb tolerance and are highly relevant for designing microalgal platforms for Pb bioremediation and metal-resilient bioprocesses
